Journal of Clinical Endocrinology & Metabolism, Vol 75, 234-238, Copyright © 1992 by Endocrine Society

ARTICLES

Reversal of diet-induced catabolism by infusion of recombinant insulin- like growth factor-I in humans

DR Clemmons, A Smith-Banks and LE Underwood
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599.

Treatment of catabolic conditions with insulin-like growth factor I (IGF-I), the peptide that mediates some of the anabolic growth- promoting effects of GH, offers potential advantages of avoiding the hyperglycemia caused by treatment with GH. A state of moderate catabolism was produced in six normal, young adult volunteers by restricting their daily dietary intake to 20 kilocalories/kg/day. During the last 6 days of two 2-week diet-study periods, they received either IGF-I (12 micrograms/kg/h by i.v. infusion over 16 h) or GH (0.05 mg/kg/day by sc injection). IGF-I improved nitrogen balance from - 236 +/- 45 mmol/day (+/- SE) during diet alone, to -65 +/- 40 mmol/day (P less than 0.001) during the last 4 days of IGF-I infusion. A similar effect was produced by GH. IGF-I infusion decreased fasting blood glucose from 4.94 +/- 0.91 mmol/L to 3.13 +/- 0.44 mmol/L (P less than 0.001), while GH raised blood glucose values (4.75 +/- 1.01 mmol/L on diet alone, to 5.48 +/- 1.00 during the period of GH treatment; P less than 0.05). Despite these differences in blood glucose, IGF-I infusions decreased serum insulin (74.9 +/- 26.8 pmol/L on diet alone, to 16.7 +/- 1.5 pmol/L during IGF-I) and serum connecting-peptide concentrations (2.14 +/- 0.89 mmol/L on diet alone, to 0.97 +/- 0.14 during IGF-I), while GH raised insulin (109.4 +/- 31.3 pmol/L, P less than 0.05 during GH) and connecting-peptide (3.12 +/- 0.59 mmol/L, P less than 0.02). At the dose of each hormone used, the attenuation of nitrogen wasting produced by infusions of IGF-I was similar in magnitude and timing to that produced by injections of GH. The reduction in serum glucose concentrations produced by IGF-I compared with the increase in glucose noted during GH treatment, could benefit hyperglycemic catabolic patients.

This article has been cited by other articles:

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				M. M. Zdanowicz and S. Teichberg Effects of Insulin-Like Growth Factor-1/Binding Protein-3 Complex on Muscle Atrophy in Rats Experimental Biology and Medicine, September 1, 2003; 228(8): 891 - 897. [Abstract] [Full Text] [PDF]

				A. Sevette, A. J. Kee, A. R. Carlsson, R. C. Baxter, and R. C. Smith Parenteral nutrition with lipid or glucose suppresses liver growth and response to GH in adolescent male rats Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E1063 - E1072. [Abstract] [Full Text] [PDF]

				D. Le Roith, C. Bondy, S. Yakar, J.-L. Liu, and A. Butler The Somatomedin Hypothesis: 2001 Endocr. Rev., February 1, 2001; 22(1): 53 - 74. [Abstract] [Full Text]

				D. R. Clemmons, A. C. Moses, M. J. McKay, A. Sommer, D. M. Rosen, and J. Ruckle The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in VivoBiological Activity J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1518 - 1524. [Abstract] [Full Text]

				K. R. Kritsch, D. J. Huss, and D. M. Ney Greater potency of IGF-I than IGF-I/BP-3 complex in catabolic parenterally fed rats Am J Physiol Endocrinol Metab, February 1, 2000; 278(2): E252 - E262. [Abstract] [Full Text] [PDF]

				D. Chrysis and L. E. Underwood Regulation of Components of the Ubiquitin System by Insulin-Like Growth Factor I and Growth Hormone in Skeletal Muscle of Rats Made Catabolic with Dexamethasone Endocrinology, December 1, 1999; 140(12): 5635 - 5641. [Abstract] [Full Text]

				L. E. Levitt Katz, R. J. Ferry Jr., C. A. Stanley, P. F. Collett-Solberg, L. Baker, and P. Cohen Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3117 - 3124. [Abstract] [Full Text]

				H. Barle, P. Essen, B. Nyberg, H. Olivecrona, M. Tally, M. A. McNurlan, J. Wernerman, and P. J. Garlick Depression of liver protein synthesis during surgery is prevented by growth hormone Am J Physiol Endocrinol Metab, April 1, 1999; 276(4): E620 - E627. [Abstract] [Full Text] [PDF]

				E. Svanberg, L. Powell-Braxton, C. Ohlsson, H. Zachrisson, and K. Lundholm The Role of the Growth Hormone/Insulin-Like Growth Factor I Axis in Stimulation of Protein Synthesis in Skeletal Muscles Following Oral Refeeding Endocrinology, December 1, 1998; 139(12): 4906 - 4910. [Abstract] [Full Text] [PDF]

				M. G. Murphy, L. M. Plunkett, B. J. Gertz, W. He, J. Wittreich, W. M. Polvino, and D. R. Clemmons MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 320 - 325. [Abstract] [Full Text]

				K. Berneis, R. Ninnis, J. Girard, B. M. Frey, and U. Keller Effects of Insulin-Like Growth Factor I Combined with Growth Hormone on Glucocorticoid-Induced Whole-Body Protein Catabolism in Man J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2528 - 2534. [Abstract] [Full Text] [PDF]

				A. F. Tarantal, M. K. Hunter, and S. E. Gargosky Direct Administration of Insulin-Like Growth Factor to Fetal Rhesus Monkeys (Macaca mulatta) Endocrinology, August 1, 1997; 138(8): 3349 - 3358. [Abstract] [Full Text] [PDF]